Cabazitaxel in Relapsed and Metastatic NSCLC

Summary

The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the fact of its significant activity and its acceptable toxicity profile.

Timeline

Start

2012-09

Primary completion

2013-08

Completion

2013-08

Drugs

Indications